Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India.
Kuila
Nivedita
N
Dash
Nilima
N
Sahoo
Devi Prasad
DP
Pattnayak
Naresh Chandra
NC
Biswas
Ghanashyam
G
Chakraborty
Soumen
S
D001483:Base Sequence; D001549:Benzamides; D001665:Binding Sites / Q000235:genetics; D015331:Cohort Studies; D004252:DNA Mutational Analysis; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D005787:Gene Frequency; D006801:Humans; D000068877:Imatinib Mesylate; D007194:India; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics*; D009154:Mutation; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D016315:Proto-Oncogene Proteins c-abl / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D016315:Proto-Oncogene Proteins c-abl